Research analysts at StockNews.com started coverage on shares of GlycoMimetics (NASDAQ:GLYC – Get Free Report) in a research note issued on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.
GlycoMimetics Price Performance
Shares of GLYC opened at $0.27 on Thursday. The company’s fifty day moving average price is $0.31 and its 200-day moving average price is $0.24. GlycoMimetics has a 1-year low of $0.14 and a 1-year high of $3.53.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in GlycoMimetics stock. Renaissance Technologies LLC grew its stake in GlycoMimetics, Inc. (NASDAQ:GLYC – Free Report) by 483.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 826,851 shares of the biotechnology company’s stock after buying an additional 685,151 shares during the quarter. Renaissance Technologies LLC owned 1.28% of GlycoMimetics worth $233,000 as of its most recent SEC filing. Institutional investors own 75.19% of the company’s stock.
About GlycoMimetics
GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
Further Reading
- Five stocks we like better than GlycoMimetics
- Stock Splits, Do They Really Impact Investors?
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Investing In Preferred Stock vs. Common Stock
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.